High national rates of high-dose dopamine agonist prescribing for restless legs syndrome.

ABSTRACT: Long-term dopamine agonist (DA) use in restless legs syndrome (RLS) is associated with augmentation, a dose-related symptom worsening leading to further dose escalation to manage RLS. This study investigated rates and factors of high-dose DA prescribing in US RLS patients. This retrospective analysis examined data from a US longitudinal prescriptions database (October 2017-September 2018). Patients diagnosed with RLS (ICD-10 G255.81) without Parkinson's disease who were prescribed ropinirole, pramipexole, and/or rotigotine were included. Daily DA dosage was categorized: LOW/MID (US Food and Drug Administration [FDA]-approved/guideline or slightly above FDA-approved [pramipexole]); HIGH (101%-149%); VERY HIGH (>150%). Patient counts were converted to US national estimates. Logistic regressi

SUBMITTER: Winkelman JW 

PROVIDER: S-EPMC8842153 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature